J&J unit seeks U.S. approval of Xarelto for ACS

Johnson & Johnson (NYSE:JNJ) unit Janssen Research & Development LLC submitted an sNDA to FDA for Xarelto rivaroxaban to reduce secondary cardiovascular events in patients with acute coronary syndrome...